Adjuvant Immunotherapy Ups Recurrence-Free Survival in Melanoma Adjuvant Immunotherapy Ups Recurrence-Free Survival in Melanoma

Dr Jeffrey Weber discusses the results of the KEYNOTE-054 trial, which demonstrated clear benefit with adjuvant pembrolizumab in patients with stage III resected melanoma.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news